The online version of this article (doi:10.1186/1475-2867-12-31) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
CNP and AP designed the study. EH, RMV, CD and EA performed experiments. AP and PJV drafted the manuscript. PJV, IAV and CNP revised the manuscript. All authors read and approved the final manuscript.
Upregulation of nuclear factor kappa B (NFκB) activity and neuroendocrine differentiation are two mechanisms known to be involved in prostate cancer (PC) progression to castration resistance. We have observed that major components of these pathways, including NFκB, proteasome, neutral endopeptidase (NEP) and endothelin 1 (ET-1), exhibit an inverse and mirror image pattern in androgen-dependent (AD) and -independent (AI) states in vitro.
We have now investigated for evidence of a direct mechanistic connection between these pathways with the use of immunocytochemistry (ICC), western blot analysis, electrophoretic mobility shift assay (EMSA) and proteasome activity assessment.
Neuropeptide (NP) stimulation induced nuclear translocation of NFκB in a dose-dependent manner in AI cells, also evident as reduced total inhibitor κB (IκB) levels and increased DNA binding in EMSA. These effects were preceded by increased 20 S proteasome activity at lower doses and at earlier times and were at least partially reversed under conditions of NP deprivation induced by specific NP receptor inhibitors, as well as NFκB, IκB kinase (IKK) and proteasome inhibitors. AD cells showed no appreciable nuclear translocation upon NP stimulation, with less intense DNA binding signal on EMSA.
Our results support evidence for a direct mechanistic connection between the NPs and NFκB/proteasome signaling pathways, with a distinct NP-induced profile in the more aggressive AI cancer state.
Authors’ original file for figure 112935_2012_347_MOESM1_ESM.tiff
Authors’ original file for figure 212935_2012_347_MOESM2_ESM.tiff
Authors’ original file for figure 312935_2012_347_MOESM3_ESM.tiff
Authors’ original file for figure 412935_2012_347_MOESM4_ESM.tiff
Authors’ original file for figure 512935_2012_347_MOESM5_ESM.tiff
Authors’ original file for figure 612935_2012_347_MOESM6_ESM.tiff
Authors’ original file for figure 712935_2012_347_MOESM7_ESM.tiff
Authors’ original file for figure 812935_2012_347_MOESM8_ESM.tiff
Authors’ original file for figure 912935_2012_347_MOESM9_ESM.tiff
Authors’ original file for figure 1012935_2012_347_MOESM10_ESM.tiff
Authors’ original file for figure 1112935_2012_347_MOESM11_ESM.tiff
Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Kaur P, Gray K, Stringer B: Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res. 2004, 10: 2466-2472. 10.1158/1078-0432.CCR-0543-3. CrossRefPubMed
Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ: The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 2008, 68: 6762-6729. 10.1158/0008-5472.CAN-08-0107. PubMedCentralCrossRefPubMed
Chen ZJ: Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005, 7: 759-763.
Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Steins H, Sundays ME, Reinherz EL: CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA. 1991, 88: 10662-10666. 10.1073/pnas.88.23.10662. PubMedCentralCrossRefPubMed
Shipp MA, Look AT: Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!. Blood. 1993, 84: 1052-1070.
Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996, 56: 663-668. PubMed
Aprikian AG, Tremblay L, Han K, Chevalier S: Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer. 1997, 72: 498-504. 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.0.CO;2-8. CrossRefPubMed
Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT, Nanus DM: Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res. 2001, 7: 1370-1377. PubMed
Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM: Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res. 2001, 61: 3294-3298. PubMed
Levine L, Lucci JA, Pazdrak B, Cheng JZ, Guo YS, Townsend CM, Hellmich MR: Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 2003, 63: 3495-3502. PubMed
Dawson LA, Maitland NJ, Turner AJ, Usmani BA: Stromal–epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer. 2006, 90: 1577-1582. CrossRef
Steiner MS: Role of peptide growth factors in prostate. Urology. 1993, 42: 88-110. CrossRef
Reile H, Armatis PE, Schally AV: Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate:ancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate. 1994, 25: 29-38. 10.1002/pros.2990250105. CrossRefPubMed
Markwalder R, Reubi JC: Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999, 59: 1152-1159. PubMed
Papandreou CN, Usmani BA, Geng Y, Bogenreider T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med. 1998, 4: 50-57. 10.1038/nm0198-050. CrossRefPubMed
Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, Nelson JB, Nanus DM: Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res. 2000, 6: 1664-1670. PubMed
Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM: Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinol. 2000, 141: 1699-1704. 10.1210/en.141.5.1699.
Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP, Nanus DM: Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol. 2000, 170: 131-142. 10.1016/S0303-7207(00)00326-9. CrossRefPubMed
Nanus DM: Of peptides and peptidases: the role of cell surface peptidases in cancer. Clin Cancer Res. 2003, 9: 6307-6309. PubMed
Muenchen HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ: Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha “super-repressor”. Clin Cancer Res. 2000, 6: 1969-1977. PubMed
Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A: The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis. 2001, 18: 471-479. CrossRef
Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV: The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci. 2002, 115: 141-151. PubMed
Patrikidou A, Vlachostergios PJ, Voutsadakis IA, Hatzidaki E, Valeri RM, Destouni C, Apostolou E, Daliani D, Papandreou CN: Inverse baseline expression pattern of the NEP/neuropeptides and NFkappaB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int. 2011, 11: 13-10.1186/1475-2867-11-13. PubMedCentralCrossRefPubMed
Abramoff MD, Magelhaes PJ, Ram SJ: Image Processing with ImageJ. Biophotonics International. 2004, 11: 36-42.
Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN: Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Int J Urol. 2012, 10.1111/j.1442-2042.2012.02967.x. Epub ahead of print
Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC: Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res. 2005, 65: 9891-9898. 10.1158/0008-5472.CAN-05-1293. CrossRefPubMed
Browatzki M, Schmidt J, Kübler W, Kranzhöfer R: Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol. 2002, 95: 98-105. CrossRef
Usmani B, Harden B, Maitland NJ, Turner AJ: Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci. 2002, 103: 3145-3175. CrossRef
- Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells
Panagiotis J Vlachostergios
Ioannis A Voutsadakis
Christos N Papandreou
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II